{"id":9355,"date":"2018-05-31T18:09:36","date_gmt":"2018-05-31T16:09:36","guid":{"rendered":"https:\/\/www.satt.fr\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/"},"modified":"2018-06-14T11:58:35","modified_gmt":"2018-06-14T09:58:35","slug":"goliver-therapeutics-sattaque-a-regenerescence-foie-greffe","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/","title":{"rendered":"Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe"},"content":{"rendered":"<p class=\"p1\">Le d\u00e9but des ann\u00e9es 2000 est marqu\u00e9 par l\u2019acc\u00e9l\u00e9ration des <strong>recherches sur les cellules souches pluripotentes humaines<\/strong>, une avanc\u00e9e biom\u00e9dicale r\u00e9compens\u00e9e par le <em>prix Nobel de M\u00e9decine en 2012 (J. Gurdon et S. Yamanaka)<\/em>. Ces cellules souches repr\u00e9sentent une avanc\u00e9e majeure pour la <strong>mod\u00e9lisation d\u2019organes et de pathologies<span class=\"Apple-converted-space\">\u00a0 <\/span>in vitro<\/strong> et pour le <strong>d\u00e9veloppement de m\u00e9dicaments de th\u00e9rapie<\/strong> fabriqu\u00e9s \u00e0 partir de cette source illimit\u00e9e de cellules th\u00e9rapeutiques.<\/p>\n<p class=\"p3\">Suite aux avanc\u00e9es majeures obtenues de ses recherches pour le <strong>traitement des maladies du foie<\/strong> au cours du programme Europ\u00e9en FP7-Innolaliv, Tuan Huy Nguyen, chercheur de l\u2019Inserm au Centre de Recherche en Transplantation et Immunologie (CRTI UMR 1064, Universit\u00e9 de Nantes &#8211; Inserm), d\u00e9cide de se lancer en 2014 dans l\u2019\u00e9laboration du projet de c<strong>r\u00e9ation de la start-up GoLiver Therapeutics<\/strong>, sp\u00e9cialis\u00e9e dans la production de cellules souches pluripotentes diff\u00e9renci\u00e9es permettant de r\u00e9parer le foie sans greffe.<\/p>\n<p class=\"p3\">Ce projet est accompagn\u00e9 depuis ses d\u00e9buts par Atlanpole, avec le soutien du CRTI-UMR1064,<span class=\"Apple-converted-space\">\u00a0de\u00a0<\/span>l\u2019IHU-Cesti et de la SATT Ouest Valorisation. Le projet GoLiver a \u00e9t\u00e9 prim\u00e9 au concours national I-Lab de soutien \u00e0 la cr\u00e9ation d\u2019entreprises de technologies innovantes en 2015 (\u00aben \u00e9mergence \u00bb) et en 2016 (le premier Grand Prix des Pays de la Loire, dans les biotechs de la sant\u00e9), et \u00e0 Start West en 2016.<\/p>\n<p class=\"p3\">GoLiver Therapeutics SAS a \u00e9t\u00e9 cr\u00e9\u00e9e en Avril 2017 et a r\u00e9alis\u00e9 une premi\u00e8re lev\u00e9e de fonds de 700.000 euros aupr\u00e8s de Business Angels et Love Money en Juin 2017.<\/p>\n<p>D\u00e9couvrez l&#8217;int\u00e9gralit\u00e9 de cette success stories sur le site de la SATT Ouest Valorisation.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le d\u00e9but des ann\u00e9es 2000 est marqu\u00e9 par l\u2019acc\u00e9l\u00e9ration des recherches sur les cellules souches pluripotentes humaines, une avanc\u00e9e biom\u00e9dicale r\u00e9compens\u00e9e par le prix Nobel de M\u00e9decine en 2012 (J. Gurdon et S. Yamanaka). Ces cellules souches repr\u00e9sentent une avanc\u00e9e majeure pour la mod\u00e9lisation d\u2019organes et de pathologies\u00a0 in vitro et pour le d\u00e9veloppement de [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":9482,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[568],"tags":[],"class_list":["post-9355","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-successstories-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charlotte PERRIER\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/\"},\"author\":{\"name\":\"Charlotte PERRIER\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/20d3c45d31431cc2a06bd3dc52c2c086\"},\"headline\":\"Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe\",\"datePublished\":\"2018-05-31T16:09:36+00:00\",\"dateModified\":\"2018-06-14T09:58:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/\"},\"wordCount\":303,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/05\/Goliver.jpg\",\"articleSection\":[\"Success Stories\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/\",\"url\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/\",\"name\":\"Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/05\/Goliver.jpg\",\"datePublished\":\"2018-05-31T16:09:36+00:00\",\"dateModified\":\"2018-06-14T09:58:35+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/20d3c45d31431cc2a06bd3dc52c2c086\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/05\/Goliver.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/05\/Goliver.jpg\",\"width\":2133,\"height\":1190},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/20d3c45d31431cc2a06bd3dc52c2c086\",\"name\":\"Charlotte PERRIER\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/charlotte\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/","twitter_misc":{"Written by":"Charlotte PERRIER","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/"},"author":{"name":"Charlotte PERRIER","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/20d3c45d31431cc2a06bd3dc52c2c086"},"headline":"Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe","datePublished":"2018-05-31T16:09:36+00:00","dateModified":"2018-06-14T09:58:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/"},"wordCount":303,"image":{"@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/05\/Goliver.jpg","articleSection":["Success Stories"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/","url":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/","name":"Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/05\/Goliver.jpg","datePublished":"2018-05-31T16:09:36+00:00","dateModified":"2018-06-14T09:58:35+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/20d3c45d31431cc2a06bd3dc52c2c086"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/05\/Goliver.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/05\/Goliver.jpg","width":2133,"height":1190},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/goliver-therapeutics-sattaque-a-regenerescence-foie-greffe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Ouest Valorisation : GoLiver Therapeutics s\u2019attaque \u00e0 la r\u00e9g\u00e9n\u00e9rescence du foie sans greffe"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/20d3c45d31431cc2a06bd3dc52c2c086","name":"Charlotte PERRIER","url":"https:\/\/www.satt.fr\/en\/author\/charlotte\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/9355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=9355"}],"version-history":[{"count":1,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/9355\/revisions"}],"predecessor-version":[{"id":9486,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/9355\/revisions\/9486"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/9482"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=9355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=9355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=9355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}